Actively Recruiting
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2025-06-18
10000
Participants Needed
1
Research Sites
1769 weeks
Total Duration
On this page
Sponsors
U
UNC Lineberger Comprehensive Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tissue and blood samples from women with locally advanced or metastatic breast cancer
CONDITIONS
Official Title
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
Who Can Participate
Eligibility Criteria
You may qualify if you...
- High suspicion of or known breast cancer (early or metastatic)
- Lesion accessible for safe biopsy (as deemed by the treating physician)
- Age 18 years or older
- ECOG performance status 0 to 2
- Ability to understand and willingness to sign an informed consent document
- If receiving therapeutic anticoagulation, it should be temporarily discontinued before biopsy as directed by the study doctor
- Adequate marrow function (absolute neutrophil count 1.5 x 10^9/L and platelets 100 x 10^9/L) required only for biopsies of vital organs (lung, liver, etc.)
You will not qualify if you...
- Presence of any disease or condition that would make participation unsafe or interfere with safety
- Dementia, altered mental status, or psychiatric conditions preventing informed consent
- History of serious or life-threatening allergic reaction to local anesthetics such as lidocaine or xylocaine
- Pregnancy due to risks associated with sedation and radiation exposure during biopsies
- Cardiac disease making biopsy unsafe as judged by the treating physician
- Receiving bevacizumab or other angiogenesis inhibitors within 6 weeks prior to biopsy of vital organs (lung, liver, etc.)
- For biopsies of breast, peripheral lymph node, or skin punch, patients must be at least 2 weeks from last dose of angiogenesis inhibitors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States, 27599-7295
Actively Recruiting
Research Team
A
Adrianna Warner
CONTACT
E
Erin Kelly
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here